# Sobi (Swedish Orphan Biovitrum)

Source: https://onco.cc/companies/sobi/  
OnCo record `sobi` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sobi is a Swedish rare-disease company whose haematology and oncology supportive products include palifermin (Kepivance) for severe oral mucositis, avatrombopag (Doptelet) and emapalumab (Gamifant).

## Summary

Swedish Orphan Biovitrum markets Kepivance (palifermin) for mucositis after high-dose chemotherapy with stem cell support, Doptelet (avatrombopag) for thrombocytopenia, Gamifant (emapalumab) for haemophagocytic lymphohistiocytosis and Zynlonta (loncastuximab tesirine) in Europe under licence from ADC Therapeutics.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Also known as: CTI BioPharma
- HQ: Stockholm
- Type: pharma
- Website: https://www.sobi.com
- Ticker: SOBI.ST

## Sources

- Official website: https://www.sobi.com

## Connected records

- drugs: [Emapalumab](https://onco.cc/drugs/emapalumab/), [Pacritinib](https://onco.cc/drugs/pacritinib/), [Palifermin](https://onco.cc/drugs/palifermin/)
- companies: [ADC Therapeutics](https://onco.cc/companies/adc-therapeutics/)
- terms: [Mucositis and stomatitis](https://onco.cc/terms/mucositis/), [Thrombocytopenia](https://onco.cc/terms/thrombocytopenia/)
- trials: [A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma](https://onco.cc/trials/nct00434161/), [Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia](https://onco.cc/trials/nct07033598/), [Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer](https://onco.cc/trials/nct00101582/), [Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)](https://onco.cc/trials/nct00109031/)

---
JSON: https://onco.cc/api/v1/entities/sobi.json